

IN THE SPECIFICATION

Page 6, line 3: after amino acid "optimized" add -- SEQ ID NO: 2 gives the sequence of FAP. SEQ ID NO: 3 gives the amino acid sequence of CD26. --.

Page 10, line 7: change "Dod" to -- Dod --.

Page 11, line 23: change "2812" to -- 2815 --;

line 24: change "2277" to -- 2280 --.

Page 12, line 10: change "61" to -- 51 --;

line 13: change "48" to -- 52 --;

line 21: change "eight" to -- nine --.

Page 13, Table 2:

after "WGWSYGG" (each occurrence) add -- SEQ ID NO: 4 --;

after "GTADDNV" (each occurrence) add -- SEQ ID NO: 6 --;

after "DQNHGLS" add -- SEQ ID NO: 7 --;

after "DEDHGIA" (each occurrence) add -- SEQ ID NO: 8 --;

after "FGWSYGG" add -- SEQ ID NO: 4 --;

after "DSDHSIR" add -- SEQ ID NO: 8 --;

after "FGKDYGG" (each occurrence) add -- SEQ ID NO: 5 --;

after "PTADEKI" and each occurrence of "ATADEKI" add -- SEQ ID NO: 9 --;

after "DESHYFT", "DESHYFH" and "DESHYFS" add -- SEQ ID NO: 10 --.

Page 14, line 2: change "describes" to -- described --;

line 12: change "kd" to -- kD --.

Page 19, line 19: change "due" to -- dye --.

Page 21, line 5: delete ",".

Page 26, line 17: following "library" change "," to -- . --, and add the following:

-- One can identify such enzyme inhibitors by combining a molecule which has FAP enzyme activity, such as the dimeric molecules of the invention, including dimers of SEQ ID NO: 2, with a substrate for the molecule with the enzymatic activity, as well as a substance believed to be an inhibitor. Then, one determines the activity of the molecule with enzymatic activity on its substrate, in the presence of the substance believed to be enzyme